Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Chance Pharmaceuticals 畅溪制药 logo — A clinical-stage biotech company focusing on discovering, de...

Chance Pharmaceuticals 畅溪制药

A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation therapies.

Founded 2015 China China 3 employees Series C Total: $175.00M Biotechnology, Health Care +1

General Information

Company Name Chance Pharmaceuticals 畅溪制药
Founded Year 2015
Location China China
Employees 3
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Chance Pharmaceuticals 畅溪制药. To contact Chance Pharmaceuticals 畅溪制药, visit chancepharmaceuticals.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Chance Pharmaceuticals 畅溪制药 compare?

A PDF of Chance Pharmaceuticals 畅溪制药 and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Chance Pharmaceuticals 畅溪制药 soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Chance Pharmaceuticals 畅溪制药

Chance Pharmaceuticals 畅溪制药 is a clinical-stage biotech company with a focus on discovering, developing, and commercializing inhalation therapies. Founded in 2015 in China, the company is dedicated to bringing transformative inhalation therapies to market for the treatment of debilitating diseases. The team, comprised of passionate and experienced experts in inhalation therapy, is committed to leveraging the potential of inhalation therapy to improve and transform the lives of individuals affected by diseases with unmet treatment needs. Recently, the company received a Series C investment from Fortune Venture Capital on 04 January 2022. With its vision, expertise, and recent investment, Chance Pharmaceuticals is poised to make a significant impact on the biotechnology, healthcare, and pharmaceutical industries.

Business keywords: clinical-stage biotech, inhalation therapy, biotechnology company, transformational therapies, respiratory diseases, chronic obstructive pulmonary disease, asthma treatment, pulmonary arterial hypertension, central nervous system disorders, drug discovery, pharmaceutical commercialization, respiratory health, clinical research, therapeutic innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C Undisclosed 1
Fortune Venture Capital
Fortune Venture Capital
04 Jan 2022
Series C $30.00M 4
Lapam Capital Shenzhen Guozhong Venture Capital Management
Lapam Capital, Shenzhen Guozhong Venture Capital Management +2
11 Oct 2021
Series B CNY80.00M 1
Yipinhong Pharmacy
16 Jun 2020
Series A CNY55.00M 3
Kaitai Capital Delian Capital Shenzhen Guozhong Venture Capital Management
Kaitai Capital, Delian Capital +1
01 Jan 2018
Angel Round CNY10.00M 1
Delian Capital
Delian Capital
01 Apr 2016

Chance Pharmaceuticals 畅溪制药 Alternatives & Competitors

View All Alternatives
Chance Pharmaceuticals 畅溪制药 vs
Relmada Therapeutics, Inc
Relmada Therapeutics, Inc United States

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of...

Post-IPO Equity
32 employees
Biotechnology, Pharmaceutical
Chance Pharmaceuticals 畅溪制药 vs
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. United States

A clinical stage pharmaceutical company developing innovative treatments for neurological disease.

Series C
22 employees
Biotechnology, Health Care
Chance Pharmaceuticals 畅溪制药 vs
Creative BioTherapeutics LLC
Creative BioTherapeutics LLC United States

An emerging biotech discovering & developing novel therapies for cancer and viruses where other opti...

6 employees
Biotechnology, Health Care
View all alternatives

FAQ About Chance Pharmaceuticals 畅溪制药

A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation therapies.
Chance Pharmaceuticals 畅溪制药 was founded in 2015.
Chance Pharmaceuticals 畅溪制药 is headquartered in China.
Chance Pharmaceuticals 畅溪制药 operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on clinical-stage biotech, inhalation therapy, biotechnology company and transformational therapies.
Chance Pharmaceuticals 畅溪制药 has approximately 3 employees.
Chance Pharmaceuticals 畅溪制药 has completed 5 funding rounds, raising a total of $175.00M. The latest funding stage is Series C.
Top alternatives and competitors to Chance Pharmaceuticals 畅溪制药 include Relmada Therapeutics, Inc, Cerebral Therapeutics, Inc., Creative BioTherapeutics LLC, SolAeroMed Inc., Orca Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Chance Pharmaceuticals 畅溪制药 and Relmada Therapeutics, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Chance Pharmaceuticals 畅溪制药, https://bouncewatch.com/company/chance-pharmaceuticals, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout